Back to Browse Journals » Journal of Blood Medicine » Volume 1

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies

Authors Jorge Castillo, Kimberly Perez

Published Date February 2010 Volume 2010:1 Pages 1—8

DOI http://dx.doi.org/10.2147/JBM.S7284

Published 25 February 2010

Jorge Castillo, Kimberly Perez

The Warren Alpert Medical School of Brown University, Division of Hematology and Oncology, The Miriam Hospital, Providence, RI , USA

Abstract: Chronic lymphocytic leukemia (CLL) is an indolent but incurable disease. Despite the improvement of the available therapies, the management of heavily-treated CLL patients represents a challenge for modern practitioners. Ofatumumab is a second-generation, fully human anti-CD20 monoclonal antibody that has shown activity in CLL patients who have failed very effective therapies such as fludarabine, alemtuzumab and rituximab. Potential benefits of ofatumumab include powerful complement-dependent cytotoxicity, less immunogenicity, faster infusions and activity in resistant CLL patients. Recently, the FDA has approved ofatumumab for the treatment of CLL patients who have failed fludarabine and alemtuzumab-based regimens. The aim of this review is to summarize the current knowledge regarding pharmacology, mechanism of action, pre-clinical and clinical development, and the role of ofatumumab for the treatment of CLL patients who have failed previous therapies. Further research is necessary to further define the role of ofatumumab in the treatment of CLL.
Keywords: ofatumumab, CLL, chronic lymphocytic leukemia, monoclonal antibodies, CD20

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies

Castillo JJ, Iyengar M, Kuritzky B, Bishop KD

OncoTargets and Therapy 2014, 7:333-342

Published Date: 21 February 2014

Readers of this article also read:

Treating thalassemia major-related iron overload: the role of deferiprone

Berdoukas V, Farmaki K, Carson S, Wood J, Coates T

Journal of Blood Medicine 2012, 3:119-129

Published Date: 19 October 2012

Role of ofatumumab in treatment of chronic lymphocytic leukemia

Veliz M, Pinilla-Ibarz J

Journal of Blood Medicine 2011, 2:71-77

Published Date: 2 May 2011

Deep vein thrombosis: a clinical review

Kesieme EB, Kesieme CN, Jebbin N, Irekpita E, Dongo A

Journal of Blood Medicine 2011, 2:59-69

Published Date: 29 April 2011

DataGenno: building a new tool to bridge molecular and clinical genetics

Fabricio F Costa, Luciano S Foly, Marcelo P Coutinho

The Application of Clinical Genetics 2011, 4:45-54

Published Date: 18 March 2011

Epigenomics in cancer management

Fabricio F Costa

Cancer Management and Research 2010, 2:255-265

Published Date: 27 October 2010

Inflammatory mediators: Parallels between cancer biology and stem cell therapy

A Patel, Andrew C Heinrich, Bobby Y Reddy, Pranela Rameshwar

Journal of Inflammation Research 2009, 2:13-19

Published Date: 4 February 2009

Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite

Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura

Journal of Inflammation Research 2008, 1:41-48

Published Date: 13 November 2008